Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Mar;105(3):152-7.
doi: 10.1034/j.1600-0404.2002.1o369.x.

A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis

Affiliations
Clinical Trial

A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis

B Fierro et al. Acta Neurol Scand. 2002 Mar.

Abstract

Objective: To investigate the efficacy of two different high doses of intravenous methylprednisolone (IVMP) during Multiple Sclerosis (MS) relapses.

Background: Transcranial Magnetic Stimulation (TMS) is the most sensitive neurophysiological ascertainment to quantify motor disability, to follow the recovery from an MS relapse, and to detect the response to treatment.

Design and method: Twenty-four clinically definite relapsing - remitting MS patients presenting a relapse were randomly assigned to a treatment for 5 days with IVMP 1 or 2 g/day. The response to treatment of each patient was evaluated through Expanded Disability Status Scale (EDSS), Medical Research Council (MRC) score, and TMS by means of motor evoked potential (MEP) parameters.

Results: Motor threshold (MT), central motor conduction time (CMCT) and MRC showed a higher improvement with the highest dose of IVMP. Silent period and EDSS improved with both treatments.

Conclusion: The dose of 2 g/day of IVMP is more effective in MS relapse.

PubMed Disclaimer

Similar articles

Cited by

Publication types

LinkOut - more resources